Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.

Cancer gene therapy - 1 Mar 2005

Conrad Charles, Miller C Ryan, Ji Yongjie, Gomez-Manzano Candeleria, Bharara Suman, McMurray John S, Lang Frederick F, Wong Franklin, Sawaya Raymond, Yung W K Alfred, Fueyo Juan

Abstract excerpt

Replication-competent adenoviruses could provide an efficient method for delivering therapeutic genes to tumors. The most promising strategies among adenovirus-based oncolytic systems are designed to exploit free E2F-1 activity in cancer cells, which in the absence of pRb activates transcription and regulates the expression of genes involved in differentiation, proliferation, and apoptosis. We previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Adenovirus E1A Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, Thin Layer

Share to Cytosine Deaminase

Share to Fluorouracil

Share to Inhibitory Concentration 50

Share to Transplantation, Heterologous

Share to Viruses

Source

Identifiers

PMID: 15650766
DOI: 10.1038/sj.cgt.7700750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.PMID 15650766Read ↗

Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.Semantic proximity Read ↗

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.Semantic proximity Read ↗

Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses.Semantic proximity Read ↗

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerationsSemantic proximity Read ↗

Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.Semantic proximity Read ↗

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read ↗

Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.Semantic proximity Read ↗

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma modelsSemantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex virusesSemantic proximity Read ↗

E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.Semantic proximity Read ↗

Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized miceSemantic proximity Read ↗

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.